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TRANSFER OF ALLERGIC CONTACT-TYPE DELAYED
SENSITIVITY IN MAN*
WILLIAM L. EPSTEIN, M.D. AND ALBERT M. KLIGMAN, M.D., PH.D.
In guinea pigs it has beei possible to transfer allergic contact sensitivity
regularly, using peritoneal exudates (1), minced spleen (2), lymph nodes (2) and
other leukocyte sources (3, 4). Mononuclear cells, most likely lymphocytes, are
thought to be the cells containing the transfer factor (5). In man, on the other
hand, instances of successful transfer have been so few that most workers are
not persuaded that this phenomenon has been conclusively demonstrated (6, 7,
8, 9, 10). The explanation which Baer et al (6, 7) and Haxthausen (8) prefer for
their occasional successes with peripheral leukocytes in man is that the recipients
probably became actively sensitized by the challenge patch test or by prior patch
tests. Furthermore, Baer et al felt that the duration of sensitivity in the recipients
(8 months or more) also spoke for an active rather than a passive process. Sim-
ilarly, erratic successes using blister fluid (the Koenigstein-Urbach technic (11,
12)), have been seriously questioned (13). Nonetheless, the issue remains sub
judice because in man Lawrence (14, 15) and others (16, 17), using peripheral
leukocytes, have had little difficulty transferring delayed tuberculin and strep-
tococcal sensitivities which are akin to, if not immunologically identical with,
allergic contact sensitivity. Recently, Lawrence (18) has reviewed brilliantly
the entire subject of delayed sensitivity.
We believe that there is no basic immunologic difference between contact
sensitivity in guinea pig and man and that the discrepancy just cited is a techni-
cal rather than an actual one. The purpose of this paper is to show that when
highly sensitive donors and sufficient numbers of leukocytes are used in the proper
recipients, it is possible to transfer contact sensitivity in man.
MATERIALS AND METHODS
Three contact allergens were employed: 1) Pentadecyl catechol (P.D.C.), one
of the allergens in dermatitis-producing plants of the genus Rhus; 2) 2, 4-dinitro-
chlorobenzene (D.N.C.B.); and 3) paranitrosodimethylaniline (N.D.M.A.).
We chose highly sensitive donors who not only showed a 4 + reaction to a
1:1,000 patch test, but whose exquisite sensitivity was indicated by positive
reactions at dilutions exceeding II: 1,000,000. The chosen subjects were naturally
sensitive to P.D.C. but were deliberately sensitized to both D.N.C.B. and N.D.
M.A. The same donor served for both N.D.M.A. and D.N.C.B. transfer studies,
but the P.D.C. donors were separate. The patch test was applied by dropping,
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under a steam of air, 0.25 ml of the test substance in acetone on the skin of the
arm within the area of a round cup 2.9 cm in diameter. The acetone evaporated,
and the test substance was deposited as fine crystals on the skin.
The recipients were Negro males between the ages of 20 and 45 years.
The recipients who received cells from D.N.C.B. and N.D.M.A.-sensitive
donors were not patch-tested prior to the study because the routine 1: 1,000
patch test is capable of sensitizing. We have dismissed the possibility of sponta-
neous sensitivity to D.N.C.B. and N.D.M.A. because in about 2,000 subjects
only 2 exhibited previous sensitivity, both to N.D.M.A. The precaution of
avoiding prior testing was not necessary with P.D.C. because a 1:100 patch test
with P.D.C. does not sensitize adults.
Material for transfer was obtained by one of three methods: 1) from bullae
produced by patch testing a sensitive subject with a suitable dilution of the spe-
cific allergen (specific bullae); 2) from bullae produced by cantharidin, 0.05%
to 0.2%, in acetone under an occlusive patch; 3) from peripheral blood. The
blister fluids were collected in 24—48 hours in a small test tube containing a
minute amount of an anticoagulant, 1 % Sequestrene® in isotonic salinet. The
amount of fluid obtained was generally 2.5 to 5.0 cc in the cantharidin induced
blisters and much less than this in specifically induced blisters. Very frequently
allergen and cantharidin were patched together to obtain a higher percentage
of lymphocytes and more fluid to work with. Two blisters were raised on each
recipient and the contents pooied without centrifugation. 150 to 300 ml of venous
blood was taken from each donor. For concentrating the leukocytes, we initially
employed the method of Minor and Burnett (19) as modified by Lawrence (15),
and although it gave satisfactory results, we substituted Gollub's technic (20)
because it yielded leukocytes in a better state of preservation. The method was as
follows:
1. All glassware was siliconized.
2. 2—3 ml of 1% Sequesterene® in isotinic saline was added as an anticoagulant to each
of several 50 ml centrifuge tubes.
3. 5 ml of 3% polyvinyl pyrollidone in saline was added to each tube to increase the
erythrocyte sedimentation rate.
4. 40—50 ml of venous blood was collected in these tubes by gravity, using a standard
blood donor set.
5. Each tube was covered with scotch tape and gently inverted 2—3 times.
6. The tubes were then centrifuged at 900 R.P.M. for 10—15 minutes.
7. The supernatant and uppermost erythrocytes, containing nearly all the leukocytes,
were transferred by pipette to narrow bottom 10 ml centrifuge tubes and washed with 1%
Sequesterene®. These tubes were then centrifuged at 900—1000 R.P.M. for 15—20 minutes.
8. The buffy coat was removed from each tube, pooled in one narrow bottom 10 ml
centrifuge tube and washed with 1% Sequesterene®. This tube was then spun at 1,000
R.P.M. for 15 minutes.
9. The leukocytic layer was collected in a small syringe for intradermal injection.
Total and differential leukocyte counts were done on cells from each source to
determine the total number of lymphocytes being injected. The lymphocytes
Ethylenediaminetetraacetate (E.D.T.A.)
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obtained by Gollub's technic generally showed good staining qualities, while
those from the blister fluids, especially cantharidin-induced ones, showed toxic
changes, notably pyknosis. In the case of 5 donors we did not separate the
leukocytes in this fashion, but used fresh whole citrated blood which was immedi-
ately transfused into each of 5 recipients.
The leukocyte suspensions from blood and the uncentrifuged blister fluids were
injected deep intradermally into several sites of the same recipient in all but one
case in which the injection was made subcutaneously. The total amount of fluid
injected ranged from 0.2 ml to 35 ml but averaged 2 ml per recipient. Frequently,
two or three donors supplied transfer material for the same recipient, but blood
leukocytes and blister fluids were never mixed in the same recipient. The chal-
lenging patch tests were done with 1:100 P.D.C. and 1:1,000 D.N.C.B. and
N.D.M.A. in acetone. In the case of P.D.C. the recipients were patch tested in
24 hours, at both the injected site and on normal skin. These were repeated on
new normal sites at 7 and 21 days and approximately at monthly intervals
after that until they reverted to negative or until the subjects were lost from
the study. With D.N.C.B. and N.D.M.A. the recipients were challenged once
or twice within the first 6 days before active sensitization due to the patch tests
became a possibility. Usually, these tests were applied 1 and 4 days after the
leukocyte injection. Occasionally, the challenge patch test was delayed to the
7th and 11th days after injection. This chance of producing active sensitization
proved to constitute a severe limitation, because we could not follow the course
of transferred N.D.M.A. or D.N.C.B. sensitivity, and transfer might well have
occurred in some subjects without our detecting it. The challenging patch tests
were not considered positive unless there was at least erythema and edema that
persisted in an active phase for three to four days. A 4+ reaction was maximal
and consisted of bullae. and the other reactions were scaled accordingly.
RESULTS
It should be noted at the outset that successful transfer resulted in a gen-
eralized state of sensitivity, a fact not always sufficient appreciated by previous
workers, who usually were at pains to demonstrate local sensitivity at the site
of injection, often without patch testing elsewhere.
Pentadecyl catechol
Transfer was accomplished in 5 out of 5 subjects receiving P.D.C. induced
blister fluid containing approximately 276,000 to 3,700,000 lymphocytes. The
reaction appeared within two to six days and lasted from three to greater than
fourteen months (Table I).
Transfer was accomplished in 4 out of 4 subjects receiving mixed P.D.C.-
cantharidin-induced blister fluid containing about 550,000 to 2,100,000 lympho-
cytes. The sensitivity appeared within two days and lasted four days to seven
months. One subject receiving only cantharidin-induced blister fluid also de-
veloped a positive reaction (Table I).
6 out of 7 subjects receiving 95,000,000 to 295,000,000 washed lymphocytes
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TABLE I
P. D. C. Transfers
Recipient Number of Lymphocytes
Patch Test Reactions
Duration
2day lwk. 3wk.
P. D. C. Blister Fluid
1
2
3
4
5
1.76 X 10
5.47 X 10
4.1 X 10
4.88 X 10
3.7 X 106
1+
2+
1+
1+
1+
1+ 1+
2+ 1+
1+ 1+
2+ 1+
2+ 2—3+
3 mos.
>14 mos.
>1 mo.
2 moe.
>6mos.
Mixed P. D. C.—Cantharidin Blister Fluid
6
7
8
9
8.84 )( 10
9.5 X 106
2.25 X 106
1.3 X 106
1+
1+
1+
1+
1+ N
N N
N N
2+ 1+
2 moe.
1 week
1 week
>1 mo.
Cant haridin Blister Fluid (uncentrifuged)
10 5.54 )( 10 1+ 1+ 1+ 6 mos.
Peripheral Leukocytes
11
12
13
6
6
14
7
1.5 X 108
2.94 X 108
2.39 X 108
1.08 X 108
2.17 X 108
No count
No count
N
N
1+
N
N
2+
1—2
1+
Negative
Negative
1+
N
2—3
1+
1+
—
1+
>5 mos.
2 mos.
>6mos.
>3 moe.
<2 moe.
Transfusions
12 1.5 )< 10 N
15 1.0 X 10 2+
2+ N >1 mo.
N 2+ >1 mo.
obtained from peripheral blood became sensitized. The sensitivity appeared
within two days to three weeks and lasted four days to greater than five months
(Table I).
2 out of 2 receiving transfusions of 500 ml whole blood became sensitized within
three to seven days (Table I).
In summary, 17 of 19 transfers in 15 subjects were successful, using all three
sources. Both failures were in the same recipient, but on a previous occasion the
subject had developed a positive reaction following injection of leukocytes from
another sensitive donor.
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TABLE II
N.D.M.A. and D.N.C.B. Transfer with Lymphocytes from Peripheral Blood
(>170 million cells)
Recip-ient*
Total Number ofDonort Lymphocytes Onset Reaction Comments
D.N.C. B.
1 1 2.28 X 1O 4 days N
2 2 1.69 X 108 4 days —1
3 1, 2 4.9 X 108 2 days —1 Reverted to neg. & then flared to
2+ in 3 weeks.
4 3,4 2.3 X108 N
5 5 2.27 X 108 4 days —1 Flared at injection sites in 2 weeks.
6 6,7 8.4 X108 N
7 1 3.0 X108 N
8 8,9 5.67 X 10 N
9 5, 10, 11 7.15 X 108 N
10 1,4,8 9.5 X 108 N
11 12 1.0 X 10 N Transfusion; 1st test 1 wk. later.
12 1 1.0 X 10 1 day —1 Transfusion; immediate patch test
13 6 1.3 X 10° 1 day —1 Transfusion; immediate patch test.
N.D.M.A.
1 1 2.28X10° N
2 2 1.69 X 108 2 days 2+
3 1, 2 4.9 X 108 2 days —1 Reverted to negative and then
flared to 3+ in 3 weeks.
4 3,4 2.3 X108 N
5 5 2.27 X 108 2 days 1+ Reverted to negative within 1 wk.
6 6,7 8.4 X108 N
7 1 3.0 X108 N
8 8,9 5.67 X 10 N
9 5, 10, 11 7.15 X 108 2 days 1+ Reverted to negative within 1 wk.
10 1, 4, 8 9.5 X 108 2 days 1+ Reverted to negative within 1 wk.
11 12 1.0 X 10° N Transfusion.
12 1 1.0 X 10° N Transfusion.
13 6 1.3 X 10° N Transfusion.
* Recipients of the same number are the same.
t Donors of the same number are the same.
Dinitrochlorobenzene and paranitrosodimethylaniline
The results of tests with these substances will be considered together because
each recipient received cell samples simultaneously from donors sensitive to
both agents (Table II).
Using cantharidin-induced and specific allergen-induced blister fluid, we did
not achieve transfer in any of 15 trials, unlike Ballestero and Mom (11).
Similarly, negative results were obtained when the yield from peripheral blood
amounted to less than 20,000,000 lymphocytes. However, when 60 to 120 million
'ymphocytes were inj ected, 1 out of 4 subjects showed a positive reaction to
D.N.C.B. at 2 days, but had become unreactive at 7 days. Fourteen days later
a flare occurred at the injection site which seemed to be no more than the appear-
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ance of active sensitization induced by the challenge patch test over that site.
Transient as this sensitivity was, we take the subsequent flare to mean that
passive transfer had actually occurred earlier. None of these same 4 recipients
acquired a passive sensitivity to N.D.M.A. With 150 million to 600 million
lymphocytes from peripheral blood, 3 of 7 subjects became sensitive to both
D.N.C.B. and N.D.M.A., and in one case it was again possible to demonstrate
a reversion to a negative patch test reaction before the onset of active sensitiza-
tion. With 600 million to 1 billion lymphocytes, none of the 3 subjects became
sensitized to D.N.C.B. but 2 showed positive reactions to N.D.M.A. that re-
verted to negative within seven days. 2 of 2 subjects receiving fresh transfusions
(500 ml), containing approximately 1 billion lymphocytes, showed a positive
reaction to D.N.C.B. appearing within one day and not elicitable at the end of
a week. The sensitivity to N.D.M.A. was not transferred by this technic. One
other subject receiving a transfusion showed negative reactions when first tested
one week after the transfusion.
The threshold level for a positive transfer with D.N .C.B. and N.D.M.A. was
greater than 170 million lymphocytes; none of the subjects receiving less than
this are included in Table II. Furthermore, it should be re-emphasized that some
cases of positive transfer may have been missed, because the possibility of the
challenge patch test inducing active sensitization severely limited the number of
patches that could be done in any one subject.
Pentadecyl catechol in Children
Children between the ages of six months and two years are generally negative
to a 1:100 P.D.C. patch test, not yet having developed a plant sensitivity, but
such a patch test will sensitize 75 % or more. It will be recalled that adults be-
have much differently in this regard and in general are not sensitized by such a
patch test. This difficulty handicapped our studies in children just as it did in
adults with D.N.C.B. and N.D.M.A. A positive transfer was obtained in only 1
out of 6 children, using 50 to 200 million lymphocytes from peripheral blood,
regardless of whether the challenge was made within the first or second week
after injection.
Pentadecyl catechol Using Hyposensitized Donors and Recipients
An interesting experiment concerned the transfer of P.D.C. sensitivity from
previously highly sensitive men who had been hyposensitized by intramuscular
injections of ten per cent P.D.C. in sesame oil, so that they had become non-
reactive to a 1:100 P.D.C. patch test. In 3 out of 4 instances their leukocytes
(45 to 100 million) were capable of transferring sensitivity to negative recipients.
On the other hand, 2 hyposensitized subjects quickly reverted to a sensitive
state after an injection of leukocytes from highly sensitized donors.
Cell-Free Blister Fluid
Since some blister fluids had transferred sensitivity with relatively few cells,
an experiment was designed to test the necessity of viable cells. Mixed canthar-
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TABLE III
Summary
Positive Transfers
(1) P.D.C.
Blister Fluid 10/10
Peripheral lymphocytes 7/9
(2) D.N.C.B.
Peripheral lymphocytes 5/13
(>170 million)
(3) N.D.M.A.
Peripheral lymphocytes 5/13
(>170 million)
(4) P.D.C. in children; peripheral lymphocytes 1/6
(5) P.D.O. from hyposensitized donors 3/4
(6) P.D.C. in hyposensitized recipients 2/2
idin-P.D.C. blister fluid was collected and centrifuged to remove the cells. In 3
out of 4 instances it was possible to transfer sensitivity when 8 to 12 ml of fluid
containing 0 to 4,000 cells/mI were injected. This demonstrated that under some
circumstances "antibody" was free in the blister fluid, and cells were not required.
In addition, the sedimented cells still were capable of transferring sensitivity.
SUMMARY OF RESULTS
A summation of the percentage of successful transfers is given in Table III.
DISCUSSION
These findings show that, as in animals, contact-type delayed sensitivity can
be transferred in humans under the proper conditions. Similarly, Good (21, 22),
in recent unpublished human studies, has transferred contact sensitivity by
means of leukocytes.
Successful transfer depends upon a number of mutually interacting variables;
namely, 1) the sensitivity of the donor; 2) the number of cells transferred; 3) the
nature of the allergen; and 4) the recipient—and probably other undefined fac-
tors.
1) The donor must be extremely sensitive. Few patients with naturally ac-
quired contact sensitivity meet this qualification.
2) Large quantities of leukocytes are required. Doubtlessly, the chief reason
for the frequency of past failures is that far too few cells were used. In this re-
spect it is interesting to compare man and the guinea pig since transfer has been
so readily accomplished in that animal, even though the degree of sensitivity is
generally much less than that of man. Skog (3, 4) found the minimal number of
cells for D.N.C.B. transfer in guinea pigs to be 224 million (nearly all lym-
phocytes). At least 170 million lymphocytes are required for D.N.C.B. transfer
in man. This number of cells requires 150 to 200 ml of blood, an amount generally
greater than that used by previous investigators. In any event, since man is a
considerably larger animal than the guinea pig, one could argue that transfer
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actually is more easily achieved in man. Lymphocyte counts in blister fluids on
the other hand are not meaningful because transfer evidently can be accomplished
with cell-free fluid, at least in man. However, it is likely that such fluids contain
the lysed products of lymphocytes and perhaps transfer factors from other
sources. In this regard it is probably significant that lymphocytes predominate
in allergic contact dermatitis blisters in contrast to the tendency for polymor-
phonuclear leukocytes to predominate in blisters provoked by primary irritants
(23, 24). Lawrence (25) and Lawrence and Pappenheimer (26) were able to trans-
fer tuberculin, streptococcal and diphtheria toxoid sensitivity when the cells were
disrupted or lysed and even with saline or serum extracts of such cells. Our own
findings with cell free blister fluids are in consonance with this; however, we
must again call attention to our failure to transfer D.N.C.B. and N.D.M.A.
sensitivity with blister fluids. The matter of transferring contact allergy by cell-
free fluids requires further investigation because Chase (27), a pre-eminent
worker in this field, as well as others (28, 29), have had no success with disrupted
cells in guinea pigs. The demonstration of transfer in the guinea pig with sonically
disrupted cells by Jeter et at (30) awaits confirmation. In view of our success in
transferring P.D.C. sensitivity with the contents of blister fluids, interest is re-
awakened in the Koenigstein-Urbach test which has fallen into disrepute. Never-
theless it would appear that success with this technic will be infrequent and
probably limited to particular contact allergens. In this respect we must question
the phenomenal success of Ballestero and Mom (11) in transferring D.N.C.B.
sensitivity, using small amounts of cantharides blister fluid raised over a patch
of previous iD.N.C.B. dermatitis. Following the details of their technic, we have
been unable to verify this observation in 4 subjects. One possible explanation
for Ballestero and Mom's success is that prior patch testing actively sensitized
their subjects. Moreover, it is curious that their positive reactions were largely
localized to the injection site, whereas in no instance have we noted such strict
localization, the sensitization being illvariably generalized.
3) The third important variable is the allergen itself, as illustrated by the
ease of transferring P.D.C. sensitivity as compared to D.N.C.B. and N.D.M.A.
A most important consideration in attempting to explain this situation is the
fact that nearly every one has been exposed to Rhus allergens, and this may in
some manner prepare the "soil". Perhaps a past sensitivity has become latent,
and the injection recalls it to a clinically recognizable state*. An alternate possibil-
ity is that the prior exposure merely altered the subject's immunologic potential
without actually sensitizing him. Our difficulty in transferring P.D.C. sensitivity
in previously unexposed children bears directly on this question and suggests
that prior exposure is important. Whatever the reasons there is no question that
some allergens are distinctly superior to others in their ability to transfer sensi-
tivity. Thus, the high percentage of turpentine transfers noted by Baer et al (6)
and Haxthausen (8) may reflect a distinct characteristic of this contact allergy.
While these workers, with admirable conservatism, questioned their own re-
sults, we believe that their positive results, while few, were valid demonstrations
of transfer.
*Dr. Marion Sulzberger first suggested this intriguing possibility to us.
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FIG. 1. a. Transfer from the same donor has produced quite different patterns of reaction
in different recipients. b. Transfer from different donors has produced similar reaction
patterns in the same recipient.
4) The fourth important variable is the individual response of the recipient.
Each recipient responded to the leukocyte injection in a manner characteristic
for himself, even though there were marked differences among recipients. In
illustrating this point we are confined to the P.D.C. data, since 1:100 patch tests
neither sensitized nor altered the existing level of sensitivity; consequently, we
were able to assess the level of sensitivity over a period of time by repeated
patches. In the first place, leukocyte injections from the same donor evoked
quite variable responses in different recipients (Figure 1A), but leukocyte in-
ections from different donors into the same recipient induced a pattern of re-
action which was characteristic for that recipient (Figure 1B). These findings
establish the recipient as a crucial agent in transfer studies. In general, according
to Chase's extensive unpublished findings (31), individuals may be divided into
three groups according to the pattern of their response. The present study, al-
though not completely ruling out other variations in patch test response, tends
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FIG. 2. Three general patterns of reaction following transfer. Individual curves may vary
considerably.
to support this concept (Figure 2): 1) the majority of subjects became positive
and reverted to a permanently negative state within one to three weeks. We as-
sume this pattern represents utilization and dissipation of passively acquired
antibody. 2) In a second group the passively acquired sensitivity gradually in-
creased to a peak level where it remained for a period of months. It is hardly
likely that this protracted state of sensitization is due to the persistence of the
injected antibodies, and a sensitization with some "active" mechanism is sug-
gested. 3) Possibly, the most instructive curve was that of the third group which
showed a bimodal response. The sensitivity appeared early, became negative
or nearly so, and then showed a persistent secondary rise. This finding raises
some interesting questions which may alter the classical concepts of the nature
of antibody in allergic contact dermatitis. There are several ways of explaining
the bimodal phenomenon, and particularly the persistence of the sensitivity.
The initial rise and fall of the curve probably reflects true passive sensitization
due to the injected antibodies and is comparable to the pattern of the subjects
of the first group. The secondary rise is more difficult to explain. It might be
possible to argue, as Baer et al (6, 7) have done, that the injection of lymphocytes
releases a substance which enhances active sensitization to the challenge patch
test. Metaxas and Metaxas-Buehler (29) would support this conclusion, but the
proof of such an action is lacking. Furthermore, this explanation does not account
for all the findings, for when Chase (31) delayed the challenging patch test for
months after injection of the recipient, sensitivity was still apparent in many
instances. An explanation which seems attractive to us is that the second limb
of the bimodal curve represents the continuing formation of antibody by the
recipient, directly induced by the primary injection of the transfer factor. In
short, the recipient directly acquires a means of propagating his original accession
of antibodies in some unknown fashion without a recognizable antigenic stimulus.
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Thus, it may be somewhat inaccurate to speak of "passive" transfer when the
sensitization persists. It is still possible, of course, that antibodies may in some
fashion serve as a stimulus for the continued production of antibodies of the
same type.
In interpreting the problems of delayed sensitivity whether of the tuberculin
or the contact type, one should avoid the pitfall of reasoning by analogy with
conventional circulating serum antibodies, such as precipitins, agglutinins, etc.,
provoked by bacterial and other antigens. A great deal is known about these latter
antibodies but it is clear that delayed hypersensitivity antibodies are of a quite
different nature. Perhaps these are not antibodies at all in the conventional
sense. This is an issue which must be kept open. To begin with, conventional
antibodies are located principally in the gamma globulin fraction of serum, but
Good (21, 22) and Porter (32) have shown that patients with agammaglobuli-
nemia can develop allergic contact dermatitis, in support of these findings, we
have seen a patient with agammaglobuhinemia who was sensitive to poison ivy
plants, iii whom we have experimentally produced a contact sensitivity to
1).N.C.B. Good (21, 22) has even "passively" transferred dinitrofluorobenzene
sensitivity from agammaglobulinemic donors to normal sub,jects by means of
leukocytes. Obviously, the gamma globulins have nothing to do with delayed
hypersensitivity. With respect to the current dispute about whether lymphocytes
or plasma cells manufacture antibodies, it seems clear that the plasma cell which
is absent in agammaglobuhinemic patients is not obligatory for the development
of delayed type sensitivity. Although the lymphocyte figures heavily in transfer
studies of delayed sensitivity, its precise role in delayed antibody synthesis has
not been worked out and it may be that they are not even the main source of
antibodies. Possibly the real iole of the lymphocyte in delayed hypersensitivity
is to act as the vehicle by which centrally produced antibodies are distributed to
the skin, accounting for the generalization of the sensitization following a local
cutaneous antigenic stimulus. The skin itself does not make these antibodies nor
does it contain sufficiently large amounts to transfer the sensitivity passively
(9, 33). Sensitive skin quickly loses its sensitivity when transplanted to a non-
sensitive homozygous twin, and contrariwise, a non-sensitive skin transplanted
into a sensitized twin acquires sensitization (34), probably from the circulating
lymphocytes.
The principal importance of transfer studies is that it opens up new paths of
research into the nature of this delayed antibody system. For example, it should
be possible now to analyze blister fluids to determine the chemical composition
of the transfer factor. Lawrence has already made such a beginning in tuberculin
allergy (18, 25).
SUMMARY
1. With the proper regard for the sensitivity of the donor, the number of cells
transferred, the antigen, and the pecularities of the recipient, it has been possible
to transfer allergic contact-type delayed sensitivity in man in a significant
number of cases.
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2. The implications of these findings in regard to the conventional concept of
delayed antibodies are discussed.
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DISCL SSION
DR. Ao0LPH ROSTENBERG, JR., (Chicago, Ill.): I want to congratulate Drs.
Epstein and Kligman on succeeding where many have failed. I was delighted to
hear this paper, both because of its intrinsic value and because it is always
pleasing to have one's views corroborated. I have always thought that the failure
to transfer an eczematous sensitization in man was because of technical reasons
rather than indicating a basic difference between man aud, say, the guinea pig.
There are many points that might he discussed, but the most important to me
is the mechanism of the transfer. Haxthausen, by other technics, furnished
evidence that there was some circulating factor in the eczematous sensitization
which he thonght was a circulating antibody. In tuberculin type sensitivity a
protein has been isolated which is said to transfer delayed type of sensitivity.
There is indirect evidence that lymphocytes release this transferring factor when
exposed to antigens. The probability is then that other cells in the sensitized
animal pick up this protein, which is not a gamma globulin but an alpha globuEn.
They then acquire the ability to react to the antigen and to release the transfer
factor and in turn can sensitize or infect new cells, so this process can go on while
antigen persists. I tried some years ago to affect a cellular transfer with a reverse
transfer technic. A few, very irregular, questionable positive results were
achieved. We put the allergen in first, arguing that it would produce the full
conjugate and then when we introduced the cells we would have maximum con-
centration of the transfer material. I think it would be interesting if Dr. Epstein
would continue this work with a reverse technic. It might require lesser amounts
of the material.
DR. RUDOLF L. BARR (New York, N. Y.): I want to congratulate Drs. Epstein
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and Kligman on a voluminous study in which they attempted passive transfer
of eczematous sensitivity by two technics which previously had been used un-
successfully, namely injections of blister fluid and of white cell suspensions, and
a novel technic, namely whole blood transfusions. Dr. Epstein was kind enough
to give me a draft of his paper to read yesterday evening. I, therefore, have had
an opportunity to look over many details of his studies which time did not permit
him to present here.
Obviously there must be an explanation for the differences in the findings of
Epstein and Kligman, on the one hand and of Haxthausen and our group on
the other. First of all the allergens used in the experiments of Epstein and Klig-
man were different from those in the studies of Haxthausen and of our group.
Second, in many of their tests Epstein and Kligman transferred much larger
quantities of cells than previous investigators. Third, t.here were certain technical
differences, especially in the preparation of white cell suspensions.
In addition to these obvious differences, however, there are a good many points
in the work of Epstein and Kligman which need further elucidation. I just want
to mention a few of these: If you raise a blister by means of the allergen itself
and then remove the blister fluid and inject it into another subject's skin, you
cannot rule out the possibility that you may have picked up and transferred
some of the allergen itself, leaving a possibility for active sensitization in the re-
cipient. Also the available data do not entirely rule out the occurrence of active
sensitization rather than of the bipha.sic reactivity based on passive sensitization
followed by active sensitization. Especially puzzling are the transfer of sensitivity
with practically cell-free blister fluid and the unexplained differences in the trans-
ferability of sensitivity to 3-pentadecylcatechol and 2,4 dinitrochlorobenzene
and to nitrosodimethylaniline.
DR. WILLIAM L. EPSTEIN (in closing): I would like to thank the discussors for
their interesting comments, and I will follow Dr. Rostenberg's suggestion.
